why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: Insights into Prostate Cancer and NMIBC from Recent Conferences

CME Credits: 1.00

Released: 2025-06-30

Bladder-sparing approaches incorporating immune checkpoint inhibitors, gene therapies, targeted agents, and novel delivery platforms are advancing the management of NMIBC. Emerging modalities in prostate cancer, including next-generation hormone therapies, PARP inhibitors, combination strategies, and radiopharmaceuticals, are similarly challenging established standards and expanding the therapeutic landscape. However, clinician education is needed to integrate these emerging therapies into practice effectively, optimize treatment sequencing, manage associated toxicities, and improve outcomes for all patients. A uro-oncology panel will compile the latest, potentially practice-changing findings from the 2025 American Urological Association Annual meeting and the 2025 ASCO Annual Meeting on the treatment of NMIBC and prostate cancer and discuss the relevance for both community and academic providers. Discussions will include strategies and considerations to incorporate novel therapies into existing treatment paradigms.


View Full Course